HealthEquity (NASDAQ:HQY) Releases FY 2026 Earnings Guidance

HealthEquity (NASDAQ:HQY) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 3.870-3.950 for the period, compared to the consensus earnings per share estimate of 3.620. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

HealthEquity Stock Performance

Shares of HQY opened at $95.67 on Friday. The firm has a market capitalization of $8.24 billion, a PE ratio of 43.89, a P/E/G ratio of 1.42 and a beta of 0.18. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average price of $96.41 and a 200 day moving average price of $96.87. HealthEquity has a 52-week low of $74.07 and a 52-week high of $116.65.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Wednesday, December 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. HealthEquity had a net margin of 14.86% and a return on equity of 12.95%. The business had revenue of $322.16 million during the quarter, compared to analysts’ expectations of $320.92 million. During the same period last year, the firm posted $0.78 earnings per share. The business’s revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. On average, sell-side analysts anticipate that HealthEquity will post 2.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on HQY shares. JMP Securities set a $122.00 price target on shares of HealthEquity in a report on Thursday. Barrington Research reissued an “outperform” rating and set a $125.00 price objective on shares of HealthEquity in a research report on Thursday. Jefferies Financial Group upped their target price on HealthEquity from $130.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Citigroup reaffirmed an “outperform” rating on shares of HealthEquity in a research note on Thursday. Finally, Wall Street Zen lowered HealthEquity from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.07.

Insider Activity at HealthEquity

In other news, EVP Delano Ladd sold 1,500 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $104.56, for a total value of $156,840.00. Following the completion of the sale, the executive vice president directly owned 75,479 shares of the company’s stock, valued at approximately $7,892,084.24. This represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Henry Fiore sold 1,781 shares of the business’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $88.21, for a total transaction of $157,102.01. Following the transaction, the executive vice president directly owned 49,795 shares in the company, valued at $4,392,416.95. This trade represents a 3.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 10,781 shares of company stock valued at $1,016,707 over the last three months. 1.50% of the stock is owned by company insiders.

Institutional Trading of HealthEquity

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HQY. CIBC Bancorp USA Inc. acquired a new stake in HealthEquity during the third quarter valued at approximately $862,000. Danske Bank A S bought a new position in shares of HealthEquity during the 3rd quarter worth approximately $1,242,000. Advisory Services Network LLC acquired a new stake in HealthEquity in the 3rd quarter valued at $207,000. Oberweis Asset Management Inc. grew its position in HealthEquity by 23.1% in the third quarter. Oberweis Asset Management Inc. now owns 140,080 shares of the company’s stock valued at $13,275,000 after acquiring an additional 26,260 shares during the period. Finally, Morningstar Investment Management LLC acquired a new position in HealthEquity during the third quarter worth $3,428,000. Institutional investors own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.